帕金森病相关血清蛋白质标志物的筛选及鉴定

 目的：探讨并初步鉴定帕金森病患者血清中相关蛋白质作为特异标志物的可能性。方法：应用表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)结合纳米磁珠技术检测44例帕金森病和60例健康对照的血清标本,应用生物信息学方法筛选差异蛋白峰,经高效液相色谱（HPLC）分离出差异蛋白，酶解后进行液质联用串联质谱（LC-MS/MS）分析，利用Xcalibur的程序组件BioWorks 3.2完成蛋白质序列数据库鉴定分析。结果：经SELDI-TOF-MS结合纳米磁珠技术筛选出质荷比m/z位于8 937的蛋白质在帕金森病中高表达(帕金森病组表达强度为27.47±16.58,正常组表达强度为5.01±3.47),有显著差异(P<0.01);6 636和8 697的蛋白质在帕金森病中低表达(帕金森病组表达强度为5.43±2.66和20.22±9.57,正常组表达强度为18.85±7.56和51.13±26.22), 有显著差异(P<0.01)。联合上述3种潜在蛋白质标志物,可区分帕金森病组和对照组，其中帕金森病患者检出率为90.0%(27/30),健康者检出率为92.5%（37/40）。对m/z为6 636、8 697和8 937的标志物进行鉴定,结果分别为载脂蛋白C-I、载脂蛋白 C-III 和补体成分3a。结论：鉴定出的载脂蛋白 C-I、载脂蛋白C-III和补体成分3a在帕金森病的诊断中具有一定价值,值得进一步研究和探讨。

Screening and identification of specific serum biomarkers of Parkinson disease

AIM：To screen the possible serum biomarkers of Parkinson’s disease. METHODS：The surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) was used to screen the serum samples from 44 cases of Parkinson’s disease and 60 control subjects. The differentially expressed protein peaks were selected and isolated with high-performance liquid chromatography (HPLC), and processed with enzyme before analysis by liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS). The data mining was performed by Xcalibur program component BioWorks 3.2. RESULTS：Three differentially expressed protein peaks were selected as potential serum biomarkers from the patients of Parkinson’s disease: the protein at 8 937 m/z peak showed significant increase (27.47±16.58 in Parkinson’s disease group, and only 5.01±3.47 in control group), and the proteins at 6 636 and 8 697 m/z peaks showed significant decreases (5.43±2.66 and 20.22±9.57, respectively, in Parkinson’s disease group, and 18.85±7.56 and 51.13±26.22, respectively, in control group). The proteins at 6 636, 8 697 and 8 937 m/z peaks were identified as apolipoprotein C-I, apolipoprotein C-III and complement 3a,respectively. Combined use of these 3 biomarkers effectively distinguished the subjects between Parkinsons disease group and control group. The detection rate of the patients with Parkinsons disease was 90.0% (27/30), and the detection rate of the healthy sibkects was 92.5% (37/40). CONCLUSION：The apolipoprotein C-I, apolipoprotein C-III and complement component 3a identified as potential markers of Parkinson’s disease have diagnostic value in clinical application.